Journal of Biological Chemistry · 2006 · 88 citations · 24 references
Life SciencesImmunologyMolecular BiologyCell SignalingGene ExpressionSignal TransductionCardiovascular DiseaseCytokine BiologyEndothelial ActivationEndothelial DysfunctionInflammatory MediatorsInflammatory SignalingAtherosclerosis Molecular MechanismsEndothelial Nitric Oxide Synthase DysfunctionInflammatory Cytokine EffectsInterleukin-6 InhibitionInterleukin-6 Mediated RegulationNitric OxideStat3 SignalingVascular Endothelial Dysfunction
Chronic activation of the acute phase response (APR) is associated with atherosclerosis. Elevated levels of interleukin-6, the major inducer of the APR, are associated with an increased risk of cardiovascular events. One of the clinical hallmarks of atherogenesis is endothelial dysfunction, characterized by a decrease in endothelial production of nitric oxide (NO). We hypothesized that interleukin-6 (IL-6) decreases endothelial NO synthase (eNOS) expression. We now show that IL-6 treatment of human aortic endothelial cells (HAEC) decreases steady-state levels of human eNOS mRNA and protein. This decrease in eNOS expression is caused in part by IL-6 inhibition of transactivation of the human eNOS promoter. To explore the mechanism by which IL-6 affects eNOS expression, we examined activation of signal transducer and transactivator-3 (Stat3). The IL-6 receptor (IL-6R) is expressed in HAEC, and Stat3 is phosphorylated in response to IL-6 stimulation of the IL-6R. We identified four consensus sequences for Stat3 binding (SIE) in the eNOS promoter at positions -1520, -1024, -840, and -540. Transfection of eNOS promoter mutants revealed that the SIE at -1024 mediates Stat3 inhibition of eNOS promoter activity. Gel-shift analysis of nuclear extracts from HAEC treated with IL-6 confirms that Stat3 binds to a complex containing the SIE at -1024. RNA silencing of STAT3 blocks the inhibitory effect of IL-6 on eNOS expression. Our data show that IL-6 has direct effects upon endothelial cells, inhibiting eNOS expression in part through Stat3. Decreased levels of eNOS may be an important component of the pro-atherogenic effect of the APR. Chronic activation of the acute phase response (APR) is associated with atherosclerosis. Elevated levels of interleukin-6, the major inducer of the APR, are associated with an increased risk of cardiovascular events. One of the clinical hallmarks of atherogenesis is endothelial dysfunction, characterized by a decrease in endothelial production of nitric oxide (NO). We hypothesized that interleukin-6 (IL-6) decreases endothelial NO synthase (eNOS) expression. We now show that IL-6 treatment of human aortic endothelial cells (HAEC) decreases steady-state levels of human eNOS mRNA and protein. This decrease in eNOS expression is caused in part by IL-6 inhibition of transactivation of the human eNOS promoter. To explore the mechanism by which IL-6 affects eNOS expression, we examined activation of signal transducer and transactivator-3 (Stat3). The IL-6 receptor (IL-6R) is expressed in HAEC, and Stat3 is phosphorylated in response to IL-6 stimulation of the IL-6R. We identified four consensus sequences for Stat3 binding (SIE) in the eNOS promoter at positions -1520, -1024, -840, and -540. Transfection of eNOS promoter mutants revealed that the SIE at -1024 mediates Stat3 inhibition of eNOS promoter activity. Gel-shift analysis of nuclear extracts from HAEC treated with IL-6 confirms that Stat3 binds to a complex containing the SIE at -1024. RNA silencing of STAT3 blocks the inhibitory effect of IL-6 on eNOS expression. Our data show that IL-6 has direct effects upon endothelial cells, inhibiting eNOS expression in part through Stat3. Decreased levels of eNOS may be an important component of the pro-atherogenic effect of the APR. The acute phase response (APR) 3The abbreviations used are: APR, acute phase response; IL, interleukin; Stat-3, signal transducer and transactivator-3; eNOS, endothelial NO synthase; HAEC, human aortic endothelial cell(s); siRNA, small interfering RNA; OSM, onconstatin M; TNF, tumor necrosis factor; EGF, epidermal growth factor. is a systemic innate inflammatory response to acute injury (1Gabay C. Kushner I. N. Engl. J. Med. 1999; 340: 448-454Crossref PubMed Scopus (5110) Google Scholar, 2Uhlar C.M. Whitehead A.S. Eur. J. Biochem. 1999; 265: 501-523Crossref PubMed Scopus (893) Google Scholar). A variety of triggers such as infection or trauma lead to the rapid synthesis and circulation of a large number of acute phase effector molecules, including anti-microbial proteins, pro-coagulant factors, and metabolic regulators. Although the APR is a rapid response to acute stress, chronic activation of the APR is associated with various diseases including cancer, autoimmune diseases, and coronary artery disease. For example, levels of acute phase effector proteins such as C-reactive protein (CRP), fibrinogen, and sICAM-1 are higher in patients with atherosclerosis or acute coronary syndromes compared with healthy controls (3Libby P. Circulation. 2001; 104: 365-372Crossref PubMed Scopus (1332) Google Scholar, 4Ridker P.M. Cushman M. Stampfer M.J. Tracy R.P. Hennekens C.H. N. Engl. J. Med. 1997; 336: 973-979Crossref PubMed Scopus (4902) Google Scholar, 5Ridker P.M. Hennekens C.H. Buring J.E. Rifai N. N. Engl. J. Med. 2000; 342: 836-843Crossref PubMed Scopus (5039) Google Scholar, 6Ridker P.M. Rifai N. Clearfield M. Downs J.R. Weis S.E. Miles J.S. Gotto Jr., A.M. N. Engl. J. Med. 2001; 344: 1959-1965Crossref PubMed Scopus (1487) Google Scholar, 7Koenig W. Sund M. Frohlich M. Fischer H.G. Lowel H. Doring A. Hutchinson W.L. Pepys M.B. Circulation. 1999; 99: 237-242Crossref PubMed Scopus (1777) Google Scholar, 8Tracy R.P. Lemaitre R.N. Psaty B.M. Ives D.G. Evans R.W. Cushman M. Meilahn E.N. Kuller L.H. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 1121-1127Crossref PubMed Scopus (768) Google Scholar). The APR may play a role in the pathogenesis of endothelial dysfunction, an early stage in atherogenesis. Interleukin-6 (IL-6) is a major activator of the acute phase response (1Gabay C. Kushner I. N. Engl. J. Med. 1999; 340: 448-454Crossref PubMed Scopus (5110) Google Scholar, 9Taga T. Kishimoto T. Annu. Rev. Immunol. 1997; 15: 797-819Crossref PubMed Scopus (1298) Google Scholar). IL-6 induces hepatocytes to activate or suppress the synthesis of a variety of acute phase response effector proteins. IL-6 initiates its action by binding to the IL-6 receptor, which is composed of two subunits: an 80-kDa IL-6-binding protein and a 130-kDa transmembrane signal-transducing component (gp130) (9Taga T. Kishimoto T. Annu. Rev. Immunol. 1997; 15: 797-819Crossref PubMed Scopus (1298) Google Scholar). Activation of IL-6 signal transduction involves gp130 dimerization, ligand-dependent tyrosine phosphorylation of Jak1, Jak2, and Tyk2, followed by tyrosine phosphorylation of signal transducer and activator of transcription 3 (Stat3). Stat3 is a transcription factor that mediates the cellular response to IL-6 (10Akira S. Nishio Y. Inoue M. Wang X.J. Wei S. Matsusaka T. Yoshida K. Sudo T. Naruto M. Kishimoto T. Cell. 1994; 77: 63-71Abstract Full Text PDF PubMed Scopus (871) Google Scholar, 11Zhong Z. Wen Z. Darnell Jr., J.E. Science. 1994; 264: 95-98Crossref PubMed Scopus (1722) Google Scholar, 12Ihle J.N. Thierfelder W. Teglund S. Stravapodis D. Wang D. Feng J. Parganas E. Ann. N. Y. Acad. Sci. 1998; 865: 1-9Crossref PubMed Scopus (95) Google Scholar, 13Schindler C. Darnell Jr., J.E. Annu. Rev. Biochem. 1995; 64: 621-651Crossref PubMed Scopus (1651) Google Scholar). Stat3 is expressed in most cell types and can be activated by other cytokines and growth factors including: IFN-α, IL-10, IL-6, IL-11, LIF (leukemia inhibitory factor), CNTF (ciliary neurotrophic factor), G-CSF (granulocyte-colony-stimulating factor), IL-12, IL-2, GH (growth hormome), EGF, PDGF (platelet-derived growth factor), and CSF-1. Jak phosphorylates Stat3 on a tyrosine residue (Tyr705) within a conserved SH2 domain, allowing homodimerization or heterodimerization with other Stat family members, nuclear translocation, and transcription activation. The specific regulatory elements that Stat3 interacts with include the APRE (acute phase response element) and the SIE (c-sis inducible element). IL-6 and other factors can also activate phosphorylation of Stat3 at a single residue (Ser727), which enhances Stat3 transcriptional activation. Since effectors of the APR are elevated in apparently healthy subjects who later develop coronary artery disease, the APR may play a role in the early stages of atherogenesis, including endothelial dysfunction (14Rader D.J. N. Engl. J. Med. 2000; 343: 1179-1182Crossref PubMed Scopus (228) Google Scholar, 15Pepys M.B. Hirschfield G.M. J. Clin. Invest. 2003; 111: 1805-1812Crossref PubMed Scopus (3015) Google Scholar). Endothelial dysfunction is characterized by decreased bioavailability of NO, caused in part by increased oxidant stress and by decreased NO synthesis (16Walford G. Loscalzo J. J. Thromb. Haemost. 2003; 1: 2112-2118Crossref PubMed Scopus (202) Google Scholar, 17Cai H. Harrison D.G. Circ. Res. 2000; 87: 840-844Crossref PubMed Scopus (3189) Google Scholar). In the vasculature, NO is normally synthesized by the endothelial isoform of NO synthase (eNOS), where it plays a protective role by inhibiting leukocyte trafficking and by decreasing platelet adhesion and aggregation (18Fulton D. Gratton J.P. Sessa W.C. J. Pharmacol. Exp. Ther. 2001; 299: 818-824PubMed Google Scholar, 19Michel T. Feron O. J. Clin. Invest. 1997; 100: 2146-2152Crossref PubMed Scopus (851) Google Scholar, 20Stuehr D.J. Biochim. Biophys. Acta. 1999; 1411: 217-230Crossref PubMed Scopus (813) Google Scholar, 21Loscalzo J. Welch G. Prog. Cardiovasc. Dis. 1995; 38: 87-104Crossref PubMed Scopus (510) Google Scholar, 22Fleming I. Busse R. Cardiovasc. Res. 1999; 43: 532-541Crossref PubMed Scopus (357) Google Scholar, 23Dudzinski D.M. Igarashi J. Greif D. Michel T. Annu. Rev. Pharmacol. Toxicol. 2006; 46: 235-276Crossref PubMed Scopus (319) Google Scholar). NO production by endothelial cells is regulated by changes in eNOS enzyme activity and gene expression. The expression of eNOS can be regulated by biophysical stimuli (such as shear stress or hypoxia), growth factors (such as TGF-β, FGF, VEGF, or PDGF), hormones (such as estrogens, insulin, angiotensin II, or endothelin 1), or NO itself (23Dudzinski D.M. Igarashi J. Greif D. Michel T. Annu. Rev. Pharmacol. Toxicol. 2006; 46: 235-276Crossref PubMed Scopus (319) Google Scholar). We now show that the APR inducer IL-6 decreases eNOS expression in human aortic endothelial cells by activating the binding of Stat3 to a specific site in the human eNOS promoter. Materials—Recombinant human IL-6 was purchased from Sigma (St. Louis, MO and Oxon, UK). ECB and growing supplements were purchased from Clonetics (Barcelona, Spain). [32P]ATP was purchased from Amersham Biosciences (3000 Ci/mmol). Antibody to eNOS, iNOS and full-length Stat3 were from BD Biosciences, Madrid, Spain). Antibody against phosphorylated Stat3 on Tyr705 was from Cell Signaling (Beverly, MA) and antibodies against Stat3 (C 20) and Stat1were from Santa Cruz Biotechnology (Santa Cruz, CA). All other reagents were purchased from Sigma (Oxon, UK). Cell Culture—Human aortic endothelial cells (HAEC) were obtained from Clonetics. HAEC were grown on gelatin-coated plates in endothelial growth media plus growth supplements. Studies were performed on confluent monolayers at passages 2-7. Toxicity was measured by measuring trypan blue dye exclusion and lactate dehydrogenase activity in the incubation media. eNOS Promoter Constructs—The 1.6-kb fragment of the eNOS 5′-flanking region was a generous gift from Dr. Thomas Michel (Brigham and Women's Hospital, Boston, MA) (24Robinson L.J. Weremowicz S. Morton C.C. Michel T. Genomics. 1994; 19: 350-357Crossref PubMed Scopus (126) Google Scholar). An eNOS promoter reporter plasmid was constructed by inserting the 1.6-kb fragment of the human eNOS promoter upstream of the firefly luciferase gene in the plasmid pGL3, as described previously (25Arnet U.A. McMillan A. Dinerman J.L. Ballermann B. Lowenstein C.J. J. Biol. Chem. 1996; 271: 15069-15073Abstract Full Text Full Text PDF PubMed Scopus (180) Google Scholar). This promoter was designated-1624 eNOS-Luc. Deletion mutants of the eNOS promoter were generated by PCR, as described previously (25Arnet U.A. McMillan A. Dinerman J.L. Ballermann B. Lowenstein C.J. J. Biol. Chem. 1996; 271: 15069-15073Abstract Full Text Full Text PDF PubMed Scopus (180) Google Scholar). Immunoblotting—Immunoblotting was performed as described previously (25Arnet U.A. McMillan A. Dinerman J.L. Ballermann B. Lowenstein C.J. J. Biol. Chem. 1996; 271: 15069-15073Abstract Full Text Full Text PDF PubMed Scopus (180) Google Scholar). In brief, cellular monolayers were washed with PBS and harvested in protein lysis buffer (1% Triton X-100, 10 mm Tris/HCl, pH = 7.6, 1 mm EDTA, 0.1% sodium deoxycholate, 500 nm sodium orthovanadate, 50 mm NaF, 0.5 mm phenylmethylsulfonyl fluoride, and 1 mg/ml of antipain and leupeptin). 25 μg of total protein were separated in a 10% SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Polyscreen, PerkinElmer Life Sciences). For protein detection, blocked membranes were incubated with specific antibodies, washed, and incubated with a secondary antibody. The immunoreactive bands were visualized with the SuperSignal detection system according to the manufacture's procedures (Pierce). Nitrite Production—Nitrite release from endothelial cells was evaluated by a fluorometric assay using 2,3-diaminonaphthalene as described. Fluorescence was determined in a PerkinElmer Life Sciences LS 50B fluorometer using excitation and emission wavelengths of 365 and 450 nm, respectively. RNA Isolation and Northern Blot Analysis—Total cellular RNA from HAEC was isolated with the guanidinium thiocyanate-phenol-chloroform method. Total RNA 10 μg was fractionated by electrophoresis through denaturing 1% transferred to Biosciences, and For Northern a fragment of human eNOS were with and using a Amersham was performed at for membranes were washed and with using an were with a human dehydrogenase eNOS Promoter was performed using previously grown to in plates were in endothelial growth media for at The eNOS promoter and a plasmid containing luciferase gene were with HAEC were incubated with the for and with media. activity was determined using the reporter according to luciferase activity was determined using a and against activity. The were as luciferase of protein. Transfection was and of the eNOS 5′-flanking region was performed with the CA). The SIE consensus in the eNOS promoter were by for the within the SIE consensus binding site P.M. Cushman M. Stampfer M.J. Tracy R.P. Hennekens C.H. N. Engl. J. Med. 1997; 336: 973-979Crossref PubMed Scopus (4902) Google Scholar, 5Ridker P.M. Hennekens C.H. Buring J.E. Rifai N. N. Engl. J. Med. 2000; 342: 836-843Crossref PubMed Scopus (5039) Google were from nuclear extracts as described previously M. C. W. C. M. D. Lowenstein C.J. Circ. Res. PubMed Scopus Google Scholar). extracts from were incubated with a containing the -1024 eNOS promoter SIE binding at for were through a The gel was and For a of was incubated in the to the of the nuclear For μg of specific against Stat3 or (Santa Cruz were in the RNA expression was in with the from according to the M. C. W. C. M. D. Lowenstein C.J. Circ. Res. PubMed Scopus Google Scholar). and as as were also from and were performed in and was at The of the data were described by analysis of followed by of the were with a The was used for other are expressed as S.E. with IL-6 eNOS that IL-6 decreases eNOS expression, were incubated for with of IL-6, and eNOS protein expression was by IL-6 decreases steady-state eNOS protein levels in a as 10 of IL-6 can decrease eNOS expression. IL-6 affects eNOS expression within of treatment We determined the effect of IL-6 upon eNOS mRNA expression. IL-6 decreases steady-state levels of eNOS treatment We also the levels by the cells in response to IL-6 IL-6 decreases the release from in a data show that IL-6 decreases eNOS expression and NO synthesis in endothelial cells in IL-6 eNOS mRNA IL-6 decreases eNOS mRNA by eNOS we treated HAEC with IL-6 or for transcription by and harvested total RNA at for in Northern analysis of eNOS IL-6 the of the eNOS mRNA that IL-6 changes in eNOS expression a transcriptional effect a decrease in mRNA IL-6 eNOS Promoter the effects of IL-6 upon the human eNOS 5′-flanking region upstream from the transcriptional We HAEC with an eNOS promoter luciferase and treated with an cells were also with a plasmid eNOS promoter transactivation was measured as firefly luciferase activity to luciferase activity. IL-6 eNOS promoter activity in endothelial cells in a Since IL-6 we examined the eNOS promoter region for Stat3 binding elements The eNOS promoter four consensus SIE P.M. Cushman M. Stampfer M.J. Tracy R.P. Hennekens C.H. N. Engl. J. Med. 1997; 336: 973-979Crossref PubMed Scopus (4902) Google Scholar, 5Ridker P.M. Hennekens C.H. Buring J.E. Rifai N. N. Engl. J. Med. 2000; 342: 836-843Crossref PubMed Scopus (5039) Google -840, and Stat3 IL-6 of eNOS which of the SIE IL-6 inhibition of eNOS expression, we constructed containing of the human eNOS promoter luciferase expression. We HAEC with human eNOS with luciferase as We IL-6 to HAEC and measured firefly and luciferase activity in cell IL-6 decreases transactivation of the full-length eNOS promoter IL-6 also decreases transactivation of the eNOS promoter IL-6 transactivation of the eNOS promoter to upstream of the eNOS regulatory region data that elements within to upstream of the eNOS transcription site IL-6 of the eNOS promoter. We to the within the eNOS promoter that IL-6 of eNOS expression. on promoter data we the SIE elements and for To which of the SIE elements at or -1024 IL-6 of the human eNOS we used to a of eNOS promoter containing a of the SIE HAEC were with mutants and with IL-6 for and cell were for luciferase activity. IL-6 decreases the eNOS promoter activity of the eNOS and IL-6 also decreases eNOS promoter activity of the eNOS promoter the SIE at IL-6 promoter activity of the eNOS promoter the SIE at -1024. data that the SIE at -1024 upstream of the eNOS transcriptional site mediates IL-6 of the eNOS promoter. IL-6 Stat3 in Endothelial the APR in part by with the IL-6 receptor which in triggers Jak phosphorylation of Stat3. The IL-6 receptor is composed of two and To the mechanism by which IL-6 eNOS expression, we Stat3 phosphorylation in response to IL-6 in endothelial We treated HAEC with IL-6 for and measured phosphorylation of Stat3. Stat3 levels within of IL-6 decrease within levels for to The IL-6 receptor is expressed in and IL-6 its expression The treatment of with a Jak was to IL-6 Stat3 phosphorylation IL-6 is of the in Stat3 in endothelial HAEC were treated with 10 IL-6 for and cell were by HAEC were treated with 10 IL-6 for in the or the of A nuclear extracts from HAEC with IL-6 were incubated with SIE or to or Stat3 or were with To that IL-6 the of Stat3 to with its response we measured binding activity in endothelial nuclear We treated HAEC with IL-6, harvested nuclear and incubated nuclear extracts with a eNOS fragment to that the Stat3 binding site SIE at -1024. were fractionated by gel and IL-6 SIE binding activity in endothelial cells treatment and treatment SIE for binding activity. of an to Stat3 a in the binding to the SIE that Stat3 is in the In an to has effect on the the IL-6 Stat3 binding to a complex containing the eNOS site data that IL-6 Stat3 with the eNOS promoter at an SIE site at Stat3 eNOS by that Stat3 mediates of eNOS, we the effects of other Stat3 activating cytokines upon eNOS protein expression. tumor necrosis factor and are of Stat3. HAEC were with OSM, EGF, or IL-6 at for and eNOS expression in to IL-6 in a treatment effect on eNOS expression. IL-6, OSM, and also production cytokines that activate the Stat3 also eNOS expression and activity. We used RNA to the role of Stat3 in IL-6 of HAEC were with Stat3 or a as Stat3 decreases Stat3 levels We treated HAEC with IL-6 for IL-6 decreases eNOS expression in cells In IL-6 has effect upon eNOS expression in HAEC with the Stat3 that Stat3 mediates IL-6 of eNOS expression by with an SIE at -1024 within the human eNOS regulatory The of is that IL-6 decreases eNOS gene expression in part by activating Stat3 binding to the eNOS 5′-flanking eNOS the of that inflammatory decrease eNOS expression Arterioscler. Thromb. Vasc. Biol. PubMed Scopus (126) Google Scholar, P. Sessa W.C. S. S. J.S. J. Clin. Invest. 1994; PubMed Scopus Google Scholar, M. J.N. S. Michel T. PubMed Scopus Google Scholar). can decrease eNOS expression by inhibiting eNOS promoter transactivation and also by eNOS mRNA M. Jr., Circ. Res. PubMed Scopus Google Scholar, J. M. S. A. Cell. Biol. 1997; 17: PubMed Scopus Google Scholar, J. 2006; Scholar). an effector of the APR, decreases eNOS expression by its mRNA S. I. P. I. Circulation. PubMed Scopus Google Scholar, S. Wang C.H. A.S. B. D.J. Circulation. PubMed Scopus Google Scholar). Our that IL-6, a major of the APR, also decreases eNOS expression. Our to the of who identified transcription factors eNOS promoter including and M. C. W. C. M. D. Lowenstein C.J. Circ. Res. PubMed Scopus Google Scholar, Arterioscler. Thromb. Vasc. Biol. PubMed Scopus (126) Google Scholar, J. Biol. Chem. Full Text PDF PubMed Google Scholar, H. G. C. Y. J. Wang Y. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar, J. J. S. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). Stat3 and eNOS Stat3 gene is two mRNA and E. R. J. R.P. J. Biol. Chem. 1996; 271: Full Text Full Text PDF PubMed Scopus Google Scholar, D. Cell. Biol. 1997; 17: PubMed Google Scholar). a binding and a transcriptional activation domain, Stat3 can with SIE elements and transcription of a binding and a transcriptional activation domain, can with SIE elements has a isoform of Stat3. The of and in cells, from to at the protein This may important of the isoform affects the of gene expression in a role of isoform in systemic S. Ann. N. Y. Acad. Sci. 2003; PubMed Scopus Google Scholar, D. S. Cell. Full Text Full Text PDF PubMed Scopus Google Scholar). an important that and and that is a as has of can the of the and it by the expression of specific Stat3 is the isoform that mediates the cell response to cytokines such as IL-6 or D. S. Cell. Full Text Full Text PDF PubMed Scopus Google Scholar). Although show that IL-6 treatment to Stat3 phosphorylation and binding to the eNOS which Stat3 isoform eNOS IL-6 eNOS in to IL-6 as a of cardiovascular as as systemic (3Libby P. Circulation. 2001; 104: 365-372Crossref PubMed Scopus (1332) Google Scholar, 4Ridker P.M. Cushman M. Stampfer M.J. Tracy R.P. Hennekens C.H. N. Engl. J. Med. 1997; 336: 973-979Crossref PubMed Scopus (4902) Google Scholar, 5Ridker P.M. Hennekens C.H. Buring J.E. Rifai N. N. Engl. J. Med. 2000; 342: 836-843Crossref PubMed Scopus (5039) Google Scholar, 6Ridker P.M. Rifai N. Clearfield M. Downs J.R. Weis S.E. Miles J.S. Gotto Jr., A.M. N. Engl. J. Med. 2001; 344: 1959-1965Crossref PubMed Scopus (1487) Google Scholar, 7Koenig W. Sund M. Frohlich M. Fischer H.G. Lowel H. Doring A. Hutchinson W.L. Pepys M.B. Circulation. 1999; 99: 237-242Crossref PubMed Scopus (1777) Google Scholar, 8Tracy R.P. Lemaitre R.N. Psaty B.M. Ives D.G. Evans R.W. Cushman M. Meilahn E.N. Kuller L.H. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 1121-1127Crossref PubMed Scopus (768) Google Scholar). IL-6 levels are elevated in and atherosclerosis. Chronic may synthesis of IL-6, which Stat3 in transcription of acute phase response such as which to the and of atherosclerosis E. Cardiovasc. Res. 2006; PubMed Scopus Google Scholar, S. P.M. Clin. Cardiovasc. Med. PubMed Scopus Google Scholar). factors for atherosclerosis are associated with endothelial dysfunction, characterized in part by a production or response to nitric Our that IL-6 decreases eNOS expression a mechanism by which the acute phase response to the of cardiovascular (14Rader D.J. N. Engl. J. Med. 2000; 343: 1179-1182Crossref PubMed Scopus (228) Google Scholar, 15Pepys M.B. Hirschfield G.M. J. Clin. Invest. 2003; 111: 1805-1812Crossref PubMed Scopus (3015) Google Scholar).
24
C-reactive protein: a critical update
Mark B. Pepys, Gideon M. Hirschfield · Journal of Clinical Investigation · 2003 · 3.4K citations · Full text